Completed PHASE3 INTERVENTIONAL 2-arm NCT03157505

Efficacy and Safety of Birch Pollen Immunotherapy in Local Allergic Rhinitis (LARbirch)

Sponsor: Medical University of Silesia

Conditions Allergic Reaction Allergic Rhinitis

Interventions Placebo and symptomatic treatment Purethal Birch immunotherapy

Updated 5 times since 2017 Last updated: May 16, 2017 Started: Jan 5, 2014 Primary completion: Dec 30, 2016 Completion: Mar 2, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03157505, this PHASE3 trial focuses on Allergic Reaction and Allergic Rhinitis and remains completed. Sponsored by Medical University of Silesia, it has been updated 5 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jun 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medical University of Silesia

Data source: Medical University of Silesia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.